Beyond the Scale: Understanding the Impact of Obesity on Women's Health
JAKARTA – Obesity is a chronic metabolic disease that can comprehensively affect women’s health, including metabolic, cardiovascular, mental, and reproductive health. Through a media discussion titled ‘The Missing Conversation: Weight and Women’s Health’, Novo Nordisk Indonesia invited the public to understand the impact of obesity across various life stages of women, including its link to hormonal and metabolic conditions such as Polyendocrine Metabolic Ovarian Syndrome (PMOS).
The discussion emphasised the importance of comprehensive, personalised, and science-based obesity management, starting from lifestyle changes to medical therapy options according to a healthcare professional’s evaluation. This issue is highly relevant considering its impact on a woman’s quality of life, from adolescence to post-menopause. In Indonesia, approximately one in four adults lives with obesity, with a significantly higher prevalence recorded in women (36.4 percent) compared to men (24.4 percent).
To dissect the link between weight and various health pillars, the discussion featured obstetrics and gynaecology specialist, Dr. Cynthia Agnes Susanto BMedSc Sp.OG. “Obesity can affect various aspects of health and reduce quality of life. In women, obesity not only increases the risk of cardiovascular disease and type 2 diabetes but also risks affecting reproductive health, ranging from menstrual cycle and ovulation disorders to an increased risk of infertility and pregnancy complications,” said Dr. Cynthia. She added that obesity must be viewed as a chronic disease requiring comprehensive management tailored to individual needs based on a doctor’s evaluation.
Dr. Cynthia further explained one example of the link between obesity and reproductive health is PMOS, previously known as Polycystic Ovary Syndrome (PCOS). This nomenclature change reflects the scientific understanding that the condition is not solely related to the ovaries but is a complex endocrine and metabolic disorder. PMOS is the most common cause of ovulatory disorders, and around 35 to 50 percent of women with this condition also experience obesity, which worsens symptoms and increases the risk of reproductive and metabolic complications. Obesity and PMOS can create a complex condition. “In some women, obesity can worsen the symptoms and metabolic impact of PMOS. Meanwhile, the hormonal and metabolic changes associated with PMOS can also make weight management more challenging,” Cynthia added, stressing that obesity requires serious attention.
As science advances, the approach to managing obesity continues to evolve. Current management involves a multidisciplinary approach tailored to individual needs, encompassing lifestyle changes, psychological support, pharmacological therapy according to medical indications, and bariatric surgery for specific patients. In this approach, lifestyle changes and medical therapy are seen as complementary to help patients achieve sustainable weight management. One development in obesity management is the availability of GLP-1 receptor agonist (GLP-1 RA) therapy, which works on the biological mechanisms that regulate hunger and satiety in the brain. According to a doctor’s evaluation and medical indications, this therapy can be an option to aid weight management, complementing lifestyle changes. More than just reducing the number on the scale, this therapy supports quality weight loss, including reducing fat mass while preserving muscle mass, potentially lowering the risk of cardiovascular disease by up to 20 percent, and improving other metabolic health parameters. The choice of obesity therapy must be determined by a doctor based on the patient’s individual condition and needs. Obesity management can be part of a holistic health approach for women, including those living with PMOS.
Associate Director, Medical and Regulatory, Novo Nordisk Indonesia, Dr. Riyanny Meisha Tarliman, reaffirmed the company’s commitment to supporting women’s health journeys. Having been in Indonesia for over 20 years, Novo Nordisk is committed to supporting science-based education and cross-stakeholder collaboration to strengthen the management of chronic diseases, including obesity. “Obesity is not just a matter of appearance but a health condition that can affect a woman’s quality of life at various stages,” she said. She added that women need accurate information to recognise the risks, seek medical help when needed, and obtain appropriate management together with healthcare professionals. To support this need, Novo Nordisk Indonesia launched the NovoCare.id site, an educational platform providing science-based information about obesity, including a BMI calculator for initial screening, facts about obesity as a chronic disease, its health impacts, and the importance of consulting a doctor to find the right management options. “Through today’s discussion and the NovoCare.id site, we hope more women feel supported in understanding the facts about obesity without stigma. Besides providing accurate medical information, NovoCare.id also helps the public find professional help by searching for doctors to start the right weight management steps,” Riyanny concluded.
Source: jawawa.id (https://jawawa.id/newsitem/beyond-the-scale-understanding-the-impact-of-obesity-on-womens-health-1785419586)
Originally published by Republika (https://retizen.republika.co.id/posts/774225/bukan-sekadar-angka-timbangan-memahami-dampak-obesitas-terhadap-kesehatan-perempuan), translated from Indonesian